Cite
HARVARD Citation
Drilon, A. et al. (n.d.). Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. European journal of cancer. pp. S6-S7. [Online].